ArticleCureus2025
When Teratomas Turn Brutal: From Indolent to Invasive in Stage IIIB Ovarian Squamous Cell Carcinoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report identifies a 74-year-old female with Stage IIIB ovarian cancer, with a specific diagnosis of squamous cell carcinoma arising in a mature teratoma. She sustained surgical cytoreduction that included gynecologic oncology, general surgery, and urology. Post-operative care was coordinated to deal with early complications and recovery by working together as a multidisciplinary team. The case delves into the rare pathophysiology of malignant transformation in teratoma related to ovarian cancer, the principles of staging, and current treatment methods. This case further emphasizes the prognostic importance of mesoappendiceal involvement, a factor that independently contributes to upstaging and indicates a higher risk for recurrence. Follow-up care consisted of advanced imaging, options for adjuvant chemotherapy, and genetic counseling/referral for testing. This case report recognizes that early identification, the importance of multidisciplinary care, and follow-up based on rare ovarian malignancies are found in each of these issues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.